Genomics-based mechanism of invasive fibroids and the establishment of a therapeutic efficacy evaluation system

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000028912

Enrollment

Unknown

Registered

2020-01-07

Start date

2020-01-10

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive fibroma

Interventions

patients with invasive fibroma:Nil

Eligibility

Sex/Gender

All

Age

2 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Peripheral whole blood samples from invasive fibroma probands and their parents. 2) Pathological tissue sections of patients with invasive fibroma.

Exclusion criteria

Exclusion criteria: Patients with infectious diseases.

Design outcomes

Primary

Measure	Time frame
Immunohistochemical;Genetic typing;	—

Countries

China

Contacts

Public ContactLihong Liu

Beijing Chaoyang Hospital, Capital Medical University

hongllh@126.com+86 010-85231788

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026